Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0K0OR
|
||||
| Former ID |
DNC013508
|
||||
| Drug Name |
1-(5-(pyridin-2-yl)oxazol-2-yl)octan-1-one
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [529193] | ||
| Formula |
C16H20N2O2
|
||||
| Canonical SMILES |
CCCCCCCC(=O)C1=NC=C(O1)C2=CC=CC=N2
|
||||
| InChI |
1S/C16H20N2O2/c1-2-3-4-5-6-10-14(19)16-18-12-15(20-16)13-9-7-8-11-17-13/h7-9,11-12H,2-6,10H2,1H3
|
||||
| InChIKey |
VLJKBQYNIDBQEJ-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Fatty-acid amide hydrolase | Target Info | Inhibitor | [529193] | |
| BioCyc Pathway | Anandamide degradation | ||||
| KEGG Pathway | Retrograde endocannabinoid signaling | ||||
| PANTHER Pathway | Anandamide degradation | ||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.